Uniunea Europeană - română - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenți pentru dermatită, cu excepția corticosteroizilor - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sanofi winthrop industrie - teriflunomidum - comprimate filmate - 14 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sanofi-aventis deutschland gmbh - insulinum glarginum - soluţie injectabilă în stilou injector (pen) preumplut - 300 u/ml

Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - seruri imune și imunoglobuline, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Uniunea Europeană - română - EMA (European Medicines Agency)

pharmaxis europe limited - manitol - fibroză chistică - tuse și preparate la rece - bronchitol este indicat pentru tratamentul fibrozei chistice (fc) la adulți cu vârsta de 18 ani și mai sus, ca un tratament adjuvant la cel mai bun standard de îngrijire.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

glaxo smithkline biologicals s.a. - belgia - vaccin rujeolic,rubeolic,urlian,varicelic,viu. - pulb+solv.pt.sol.inj. in seringa preumpluta - vaccinuri virale vaccinuri rujeolice

Republica Moldova - română - ANSA (Agenţia Naţională pentru Siguranţa Alimentelor)

Смешные Свинья srl - Витаминным şi Минерале - purcei

Republica Moldova - română - ANSA (Agenţia Naţională pentru Siguranţa Alimentelor)

Смешные Свинья srl - Витаминным şi Минерале - purcei

Republica Moldova - română - ANSA (Agenţia Naţională pentru Siguranţa Alimentelor)

Смешные Свинья srl - Витаминным şi Минерале - scroafe

Republica Moldova - română - ANSA (Agenţia Naţională pentru Siguranţa Alimentelor)

srl Смешные Свинья - Витаминным şi Минерале - scroafe